LYCOS RETRIEVER 
2005
built 242 days ago
The awards committee of the 2005 Richard Tapia Celebration of Diversity in Computing Conference is seeking nominations for the Richard A. Tapia Achievement Award for Scientific Scholarship, Civic Science, and Diversifying Computing. The Tapia award recognizes an individual with outstanding achievements in scientific scholarship, a strong civic presence within the scientific community, and a dedication to the attainment of true ethnic diversity in computing and related disciplines. The deadline for submitting nominations is Wednesday, Aug. 31, 2005. Read more.
Source:
The 2005 National Thanksgiving Turkey and its alternate are from Henning, Minnesota and were raised under the direction of National Turkey Federation Chairman Pete Rothfork. Mr. Rothfork delegated the day-to-day responsibilities to James and Vicki Trites of Henning. The birds are commercial turkeys used in normal industry production, and they were raised using the same techniques as other commercial birds. They were fed a regular diet of corn and soybean meal and were provided a continuous supply of fresh water.
Source:
ATLANTA, GA, Dec. 12, 2005 /PRNewswire-FirstCall/ - Cell Genesys, Inc. (Nasdaq: CEGE) today reported encouraging clinical data from a Phase 2 trial of GVAX® vaccine for chronic myelogenous leukemia (CML). Nineteen CML patients with molecular evidence of persistent leukemia despite more than one year of Gleevec® (imatinib mesylate) therapy were treated with GVAX vaccine for leukemia while continuing to receive Gleevec. The initial findings of this trial indicate that the addition of the vaccine to Gleevec therapy has reduced persistent leukemic disease in 9 of 19 patients to date as demonstrated by a complete disappearance (five patients) or a greater than one log (90%) reduction (four patients) in bcr-abl -- a validated genetic marker found on the leukemic cells. Of the remaining 10 patients, only one patient has progressed on therapy with GVAX vaccine for leukemia while the other 9 continue to be monitored for reductions in bcr-abl. Reductions of bcr-abl have been previously shown to be strongly associated with improved progression-free survival in patients with CML. The trial was conducted at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center by Dr. Hyam Levitsky, professor of Oncology Medicine and Urology, and colleagues, and the data were presented today at the annual meeting of the American Society of Hematology (ASH) in Atlanta, GA (ASH Abstract #2858).
Source:
PRINCETON, N.J., Feb 23, 2005 /PRNewswire-FirstCall via COMTEX/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the Wells Fargo Securities 2005 Healthcare Conference at 1:30 PM Eastern Time on March 2, 2005. The conference is being held at The St. Regis Hotel in New York. Medarex's presentation will be webcast live and will be available for replay through the Webcasts page in the Investor Relations section of the Medarex website via the Internet at http://www.medarex.com. Medarex is a biopharmaceutical company focused on the discovery and development of fully human antibody-based therapeutics to treat life- threatening and debilitating diseases, including cancer, inflammation, autoimmune and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody products for itself and its partners. Twenty-one of these therapeutic products derived from Medarex technology are currently in human clinical testing, with the most advanced product presently in a Phase III clinical trial.
Source:
HAMBURG, Germany, December 06, 2005 /PRNewswire-FirstCall/ — Evotec AG announced today that the first milestone has been achieved in its four-year drug discovery collaboration with Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”). Evotec has granted Takeda exclusive rights in a novel target in Alzheimer’s disease based on successful target identification and validation work triggering a milestone […]
Source:
The 46th Annual Symposium on Foundations of Computer Science (FOCS 2005), sponsored by the IEEE Computer Society Technical Committee on Mathematical Foundations of Computing, will be held at the Omni William Penn Hotel in Pittsburgh, PA on October 23-25, 2005. Tutorials will be held October 22 (at CMU).
Source:
MORE ABOUT
2005